

# Vitamin K supplementation reduces serum concentrations of under- $\gamma$ -carboxylated osteocalcin in healthy young and elderly adults<sup>1-3</sup>

Neil C Binkley, Diane C Krueger, Jean A Engelke, Andrea L Foley, and John W Suttie

## ABSTRACT

**Background:** Subclinical vitamin K insufficiency, manifested by under- $\gamma$ -carboxylation of the bone matrix protein osteocalcin, may be common.

**Objective:** Our objective was to delineate the prevalence of submaximal  $\gamma$ -carboxylation as assessed by response to phylloquinone supplementation and to evaluate the effect of this intervention on skeletal turnover in healthy North American adults.

**Design:** Healthy subjects ( $n = 219$ ), approximately equally distributed by sex and age (18–30 y and  $\geq 65$  y), received daily phylloquinone (1000  $\mu\text{g}$ ) or placebo for 2 wk. Serum undercarboxylated osteocalcin (ucOC) and total osteocalcin, *N*-telopeptides of type I collagen (NTx), bone-specific alkaline phosphatase (BSAP), and phylloquinone concentrations were measured at baseline and after weeks 1 and 2.

**Results:** At baseline, the mean serum phylloquinone concentration was lower in the young than in the old group; there was no effect of sex. Concomitantly, baseline %ucOC was highest in the young and lowest in the old men ( $P < 0.0001$ ) but did not differ significantly by age in women. After supplementation, serum phylloquinone concentration increased  $\approx 10$ -fold ( $P < 0.0001$ ) at week 1 (from  $0.93 \pm 0.08$  to  $8.86 \pm 0.70$  nmol/L,  $\bar{x} \pm \text{SEM}$ ); this was sustained through week 2. Among all supplemented groups, mean %ucOC decreased from 7.6% to 3.4% without significant differences by age or sex; 102 of 112 subjects had a  $> 1\%$  decrease. Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration.

**Conclusions:** Usual dietary practices in this population did not provide adequate vitamin K for maximal osteocalcin carboxylation. Phylloquinone supplementation reduced serum osteocalcin concentration but did not alter other markers of serum bone turnover. *Am J Clin Nutr* 2000;72:1523–8.

**KEY WORDS** Vitamin K, phylloquinone, osteocalcin, undercarboxylated osteocalcin, ucOC, bone turnover, osteoporosis, elderly

## INTRODUCTION

Undercarboxylation of the bone matrix protein osteocalcin appears to be a sensitive measure of vitamin K status (1–3). When defined as elevated concentrations of undercarboxylated osteocalcin (ucOC), vitamin K insufficiency appears to be com-

mon in postmenopausal women (4, 5). Whether this insufficiency has clinical relevance is unclear. However, a high serum ucOC concentration has been associated with skeletal turnover (6), low bone mineral density (7), and increased risk of osteoporotic fracture (8–10). Additionally, clinical use of vitamin K antagonists as anticoagulants has been related to low bone mineral density (11–15) and increased risk of fracture (16). These observations imply that vitamin K insufficiency contributes to osteoporosis development. If these associations are causally related, ie, if undercarboxylation of osteocalcin produces adverse skeletal consequences, increased vitamin K intake is indicated. However, such a recommendation is premature because other reports showed no effect of warfarin-induced vitamin K insufficiency on bone density (17–19) or fracture (20). As such, the role of vitamin K insufficiency in skeletal health remains unclear. The purpose of this study was to further delineate the prevalence of submaximal  $\gamma$ -carboxylation, as assessed by response to vitamin K supplementation, and to evaluate the effect of this intervention on skeletal turnover in young and old individuals of both sexes.

## SUBJECTS AND METHODS

### Subjects

This study was approved by the University of Wisconsin Health Sciences institutional review board and informed consent was obtained from all volunteers. The study population consisted of 219 healthy subjects recruited from central and southern Wisconsin (**Table 1**). Age groups were arbitrarily defined as young (18–30 y of age) and old ( $\geq 65$  y of age). Approximately equal numbers of men and women were enrolled in both age groups. Screening laboratory values, including prothrombin time (PT), complete blood count, and a serum chemistry panel, were

<sup>1</sup>From the Institute on Aging, Department of Medicine, and the Department of Biochemistry, University of Wisconsin, Madison.

<sup>2</sup>Supported in part by the NIH (grant AG00801) and by Roche Vitamins Inc, Parsippany, NJ.

<sup>3</sup>Address reprint requests to NC Binkley, 2245 MSC, 1300 University Avenue, Madison, WI 53706. E-mail: nbinkley@facstaff.wisc.edu.

Received December 14, 1999.

Accepted for publication May 15, 2000.

**TABLE 1**  
Demographic data<sup>1</sup>

Group	Age	BMI	Compliance	Withdrawn from study
	y	kg/m <sup>2</sup>	%	n
Young men (n = 55)	24.8 ± 0.4	25.4 ± 0.4	89 ± 1.5 <sup>2</sup>	2
Phylloquinone (n = 28)	25.3 ± 0.6	25.5 ± 0.7	90 ± 2.1	0
Control (n = 27)	24.2 ± 0.6	25.4 ± 0.6	88 ± 2.2	2
Young women (n = 55)	24.2 ± 0.5	23.0 ± 0.5 <sup>2</sup>	93 ± 1.3	5
Phylloquinone (n = 28)	24.4 ± 0.7	22.9 ± 0.7	94 ± 1.7	2
Control (n = 27)	24.1 ± 0.6	23.2 ± 0.8	92 ± 2.1	3
Old men (n = 53)	75.8 ± 0.7	26.9 ± 0.7	96 ± 1.1	2
Phylloquinone (n = 27)	75.3 ± 1.1	26.7 ± 0.7	97 ± 1.3	1
Control (n = 26)	76.3 ± 1.1	27.1 ± 1.3	94 ± 1.9	1
Old women (n = 56)	75.4 ± 1.0	25.4 ± 0.6	96 ± 1.7	4
Phylloquinone (n = 29)	74.9 ± 1.4	25.4 ± 0.9	99 ± 0.7	1
Control (n = 27)	75.9 ± 1.5	25.6 ± 0.9	94 ± 3.3	3

<sup>1</sup> $\bar{x} \pm \text{SEM}$ .<sup>2</sup>Significantly different from all other groups,  $P < 0.05$ .

required to be normal or without clinically significant abnormalities for enrollment. Volunteers with a medical history of renal or hepatic disease or malabsorption or who were receiving current warfarin therapy were excluded from participation.

### Study design

In this single-blind, placebo-controlled trial, subjects were unaware of their random assignment to receive either two 500- $\mu\text{g}$  tablets of phylloquinone (vitamin K1; Roche Vitamins Inc, Parsippany, NJ) or a matching placebo with the evening meal for 14 d. Compliance with study preparation was evaluated by tablet counts after 1 and 2 wk. Concomitant use of medication and nutritional supplements was documented before and during the study.

Serum and plasma were obtained at baseline and at the end of both treatment weeks. Blood samples were obtained by routine venipuncture between 0800 and 1100 after subjects fasted for  $\geq 8$  h. Specimens were shielded from light and allowed to clot at room temperature for 30 min before centrifugation a  $750 \times g$  for 15 min at room temperature. Aliquots were quick-frozen in liquid nitrogen and stored at  $-80^\circ\text{C}$  until thawed for analysis.

### Assays

Serum phylloquinone, osteocalcin, ucOC, bone-specific alkaline phosphatase (BSAP), and *N*-telopeptides of type I collagen (NTx) concentrations were measured for all time points. PT and decarboxyprothrombin, ie, the protein induced by phylloquinone absence or antagonist-II (PIVKA-II) were evaluated at the baseline and week 2 visits.

PT was determined by adding 2 parts Simplastin (Organon Teknika Corporation, Durham, NC) to 1 part freshly thawed (at  $37^\circ\text{C}$ ) citrated plasma in a fibrometer (Becton Dickinson, Franklin Lakes, NJ). PIVKA-II values were measured at baseline and at week 2 by enzyme-linked immunosorbent assay (ELISA, Asserachrom; Diagnostica Stago, Asnieres-sur-Seine, France). Serum phylloquinone concentrations were determined by HPLC separation with fluorescence detection (21). BSAP was measured by enzyme immunoassay (Alkphase-B; Metra Biosystems, Mountain View, CA). Serum NTx was measured by using a competitive-inhibition ELISA (Osteomark, Ostex International, Inc, Seattle). Osteocalcin was determined by immunoradiometric assay (ELSA-OSTEO; CisBio International, Gif-sur-

Yvette, France). The concentration of ucOC was determined by modification of the hydroxyapatite binding assay (22). Briefly, 500 mL serum was treated with 25 mg hydroxyapatite (no. 4280; Mallinkrodt, Inc, Paris, KY) and rotated end-over-end for 30 min at  $4^\circ\text{C}$ . The samples were then centrifuged at  $16000 \times g$  for 5 min. The supernate was removed and analyzed for osteocalcin by immunoradiometric assay. Percentage ucOC was calculated as the ratio of unadsorbed, ie, remaining in the supernate, to total osteocalcin, multiplied by 100.

### Statistical analysis

Study groups were defined by sex, treatment (phylloquinone or control), and age (young and old). Baseline comparisons of variables between groups were performed by using Student's *t* test. Spearman's rank correlation coefficient (*r*) was used to evaluate the relation of baseline serum phylloquinone concentration with osteocalcin and %ucOC. Change over time in serum phylloquinone, %ucOC, and osteocalcin was evaluated by repeated-measures analysis of variance (ANOVA) with full interaction. All analyses were conducted by using STATVIEW software (version 4.5; Abacus Concepts, Berkeley, CA).

## RESULTS

### Subjects

The demographic characteristics of the young and old groups were not significantly different by age or sex, with the exception of a lower body mass index ( $P < 0.01$ ) in the young female group (Table 1). Screening laboratory values for all groups were within the normal range (data not shown). Within the age and sex categories, there were no significant differences in demographics or baseline laboratory results between the phylloquinone and control groups (Table 1). Compliance and adherence were excellent but were lower in the young male group than in any other group; no other compliance differences were observed. Some 94% of volunteers enrolled completed the study; withdrawals were evenly distributed across groups (Table 1). No study participants used nutritional supplements other than calcium or vitamins (most frequently one multiple vitamin daily). Supplement use did not differ significantly between the control and phylloquinone-treated groups.

**TABLE 2**  
Baseline laboratory values<sup>1</sup>

Group	Phylloquinone	ucOC	Osteocalcin	NTx	BSAP
	nmol/L	%	μg/L	BCE	U/L
Young men (n = 55)	0.68 ± 0.06	9.0 ± 0.3	31.1 ± 1.4	18.9 ± 1.1	24.5 ± 1.4
Phylloquinone (n = 28)	0.71 ± 0.08	8.8 ± 0.5	29.2 ± 1.7	19.3 ± 1.6	26.2 ± 2.2
Control (n = 27)	0.66 ± 0.08	9.3 ± 0.4	33.0 ± 2.1	18.4 ± 1.5	22.6 ± 1.7
Young women (n = 55)	0.72 ± 0.09	7.7 ± 0.3 <sup>2</sup>	25.3 ± 1.0 <sup>2</sup>	13.3 ± 0.7 <sup>2</sup>	22.5 ± 1.5
Phylloquinone (n = 28)	0.63 ± 0.07	8.0 ± 0.5	25.3 ± 1.5	12.9 ± 1.0	22.6 ± 2.3
Control (n = 27)	0.81 ± 0.16	7.4 ± 0.4	25.2 ± 1.5	13.7 ± 0.9	22.4 ± 1.8
Old men (n = 53)	1.03 ± 0.14 <sup>3</sup>	6.3 ± 0.3 <sup>2</sup>	22.2 ± 1.3 <sup>2</sup>	12.3 ± 0.8 <sup>2</sup>	23.7 ± 1.5
Phylloquinone (n = 27)	1.06 ± 0.19	6.3 ± 0.4	20.7 ± 1.9	11.1 ± 1.0	22.8 ± 2.1
Control (n = 26)	1.00 ± 0.22	6.3 ± 0.4	23.8 ± 1.6	13.5 ± 1.2	24.6 ± 2.1
Old women (n = 56)	1.16 ± 0.12 <sup>3</sup>	7.4 ± 0.3 <sup>2</sup>	23.1 ± 1.7 <sup>2</sup>	13.4 ± 1.0 <sup>2</sup>	23.2 ± 1.3
Phylloquinone (n = 29)	1.26 ± 0.20	7.6 ± 0.5	24.1 ± 2.6	15.0 ± 1.5	21.7 ± 1.8
Control (n = 27)	1.06 ± 0.12	7.2 ± 0.5	22.1 ± 2.1	11.4 ± 0.9	25.2 ± 1.9

<sup>1</sup> $\bar{x} \pm \text{SEM}$ . ucOC, undercarboxylated osteocalcin; NTx, N-telopeptides of type I collagen; BSAP, bone-specific alkaline phosphatase; BCE, bone collagen equivalents.

<sup>2</sup>Significantly different from young men,  $P < 0.05$ .

<sup>3</sup>Significantly different from young men and young women,  $P < 0.05$ .

### Baseline comparisons

Mean serum phylloquinone values ranged from 0.68 to 1.16 nmol/L and were lower in young individuals of both sexes (Table 2). These baseline values correlated negatively with %ucOC and were unrelated to total osteocalcin concentration (Figure 1). Individual serum %ucOC values ranged from 2.2% to 15.3%; group means were 6.3–9.0%, being highest in young and lowest in old men ( $P < 0.05$ ); no significant age difference was found in women. Serum osteocalcin and NTx concentrations were highest in young men ( $P < 0.05$ ); no other significant age or sex differences were observed. Within age and sex categories at baseline, no significant differences in %ucOC, osteocalcin, phylloquinone, NTx, or BSAP were present between the phylloquinone-treated and control groups (Table 2). PT and all but 2 PIVKA-II values were within normal ranges and not significantly different by age or sex (data not shown).

### Phylloquinone supplementation effects


Supplementation led to an  $\approx 10$ -fold increase ( $P < 0.001$ ) in serum phylloquinone by week 1, and this effect persisted through week 2. The increase was greater in the old than in the young subjects ( $P < 0.001$ ; Figure 2), with no observed sex dif-

ference (data not shown). In the supplemented group, %ucOC decreased to  $\approx 3\%$  after 1 wk ( $P < 0.001$ ); this effect was sustained through week 2, with no significant age (Figure 3) or sex differences (data not shown). Furthermore, %ucOC was reduced by more than one percentage point in 102 of 112 individuals who received phylloquinone for 1 wk (data not shown).


Serum osteocalcin decreased ( $P < 0.001$ ) by the end of week 1; this effect was maintained at the end of week 2. No significant age or sex difference was observed (Figure 4; age and sex data not shown). To further assess skeletal turnover, NTx and BSAP concentrations were measured and showed no change with supplementation (data not shown). Additionally, when PT and PIVKA-II values were evaluated to determine the effect of phylloquinone on coagulation parameters, no change was observed (data not shown).

### DISCUSSION

In this study, supplementation promptly increased serum phylloquinone concentration and reduced %ucOC in almost all supplemented individuals. This occurred in healthy subjects who had normal coagulation variables and whose baseline phylloquinone concentrations were similar to those reported previously in healthy adults (1, 2, 23), showing that usual dietary practices



**FIGURE 1.** Baseline serum phylloquinone concentrations. At baseline, serum phylloquinone concentration ( $n = 219$ ) was negatively correlated with the percentage undercarboxylated osteocalcin (%ucOC). Serum phylloquinone and total osteocalcin concentrations were not significantly correlated.



**FIGURE 2.** Effect of supplementation on serum phyloquinone concentration. Serum phyloquinone increased significantly in all supplemented groups compared with their respective control groups ( $P < 0.0001$ ). The rise in serum phyloquinone concentration was significantly greater in the older group and did not differ by sex ( $P < 0.0001$ ).  $\bar{x} \pm$  SEM. \*Significantly different from respective control group,  $P < 0.0001$ . †Significantly different from the young, phylloquinone-supplemented group,  $P < 0.0001$ .

provide inadequate phyloquinone to allow maximal osteocalcin  $\gamma$ -carboxylation. Less than maximal  $\gamma$ -carboxylation of vitamin K-dependent proteins has been suggested to be a more sensitive definition of vitamin K deficiency than are coagulation measures (2, 24–26). However, whether the high prevalence of vitamin K insufficiency observed in this study has physiologic relevance is unclear.


In contrast with some prior reports (4, 5), %ucOC was not highest in postmenopausal women. In fact, %ucOC was comparably elevated in young women and highest in young men. This may reflect low vitamin K intake in the young group, which comprised primarily college students. If maximal osteocalcin  $\gamma$ -carboxylation is important for peak bone mass accrual, the vitamin K insufficiency observed in young men and women might be of physiologic importance.

Accumulating evidence suggests that vitamin K insufficiency contributes to the development of osteoporosis (27). However, much of this evidence is based on submaximal osteocalcin  $\gamma$ -carboxylation, ie, elevated ucOC was associated with low bone mass (7) and increased risk of osteoporotic fracture (9, 10). Additionally, individuals with vitamin K intakes in the lowest quintile were observed recently to be at increased risk of hip fracture (28). Although these findings implicate vitamin K in skeletal health, the observed associations do not establish that vitamin K insufficiency causes osteoporosis (29). Furthermore, a mechanism by which impaired osteocalcin  $\gamma$ -carboxylation could contribute to bone loss has not been defined. In this regard, the results of our study suggest that submaximal  $\gamma$ -carboxylation might lead to a state of high skeletal turnover because phyloquinone supplementation reduced serum osteocalcin, an accepted marker of bone formation (30). This observation is to some extent congruent with the recent finding that 15 d of dietary vitamin K depletion led to increased bone turnover as measured by serum osteocalcin and

urinary NTx concentration; these markers were subsequently normalized by 10 d of phyloquinone repletion ( $\approx 200 \mu\text{g/d}$ ) (31). On the basis of these observations, we speculated (32) that vitamin K insufficiency impairs the function of the calcium homeostatic system (33, 34), thereby requiring increased skeletal turnover. Because elevated skeletal turnover is associated with rapid bone loss (35), if vitamin K insufficiency accelerates bone turnover, then vitamin K insufficiency would be anticipated to contribute to the development of osteoporosis.


This speculation requires further study because other studies showed no change (2) or an increase in serum markers of bone turnover after phyloquinone supplementation (6, 36). Furthermore, anticoagulant-induced vitamin K insufficiency has been associated with unchanged (11) or decreased (14, 19, 37) serum osteocalcin concentration. Additionally, our study showed no effect of vitamin K supplementation on other biochemical measures of bone turnover (NTx and BSAP) despite the study's power to detect changes of 5% and 9%, respectively. This may suggest that osteocalcin is the first biochemical marker of bone turnover affected by phyloquinone supplementation. Had the duration of supplementation been extended, perhaps a change in NTx and BSAP would have been observed. Alternatively, one may speculate that the antibody used in our osteocalcin assay might have a lower affinity for carboxylated osteocalcin, leading to a reduction in measured serum osteocalcin. Thus, the effect, if any, of phyloquinone supplementation on bone turnover remains to be clarified. Phyloquinone supplementation studies using longer observation periods and markers of bone turnover that are not  $\gamma$ -carboxylated (eg, NTx and BSAP) should clarify this issue. Given the high prevalence of both osteoporosis and submaximal  $\gamma$ -carboxylation of osteocalcin, elucidation of the effect of phyloquinone on bone turnover is required.

Note that the phyloquinone supplement dose (1000  $\mu\text{g/d}$ ) chosen was empirical and based on previous reports. Because pharmaceutical supplements provide greater vitamin K bioavailability than does food, achievement of a comparable intake from the diet would require consumption of  $\approx 2000$ –5000  $\mu\text{g}$  vitamin K/d (2, 38).



**FIGURE 3.** Effect of phyloquinone supplementation on serum undercarboxylated osteocalcin (ucOC) compared with a placebo control in young and old subjects. Supplementation significantly decreased %ucOC to  $\approx 3\%$  ( $P < 0.0001$ ); this effect did not differ by age or sex.  $\bar{x} \pm$  SEM. \*Significantly different from respective control group,  $P < 0.0001$ .





**FIGURE 4.** Effect of phylloquinone supplementation on serum osteocalcin. Supplementation significantly decreased total osteocalcin  $\approx 9\%$  (from  $25.0 \pm 1.1 \mu\text{g/L}$  at baseline to  $22.8 \pm 1.0 \mu\text{g/L}$  at 1 wk;  $P < 0.005$ ). No change was observed in the control group.  $\bar{x} \pm \text{SEM}$ . \*Significantly different from respective control,  $P < 0.005$ .

This intake is markedly higher than current recommendations (39), which were based on coagulation parameter measurements and would be essentially impossible to obtain from food alone. Although the phylloquinone dose required to maximize osteocalcin  $\gamma$ -carboxylation is unknown, it appears likely that dietary supplementation will be required if elevated ucOC is determined to produce adverse skeletal effects because many individuals do not consume even the currently recommended amounts (23).

Older individuals were observed to have higher serum phylloquinone concentrations both at baseline and after supplementation than did younger individuals. Because triacylglycerol-rich lipoproteins are carriers of phylloquinone (40), plasma concentrations of phylloquinone and triacylglycerol are positively correlated (41), and triacylglycerol concentration increases with advancing age (42, 43), it is probable that the phylloquinone concentrations reflect higher triacylglycerol with advancing age. Serum triacylglycerol concentrations were not measured in this study.

In conclusion, usual dietary vitamin K intake of both young and old individuals is inadequate to allow maximal osteocalcin  $\gamma$ -carboxylation. Thus, if submaximal  $\gamma$ -carboxylation is used to define vitamin K status, insufficiency is widespread. Determination of the physiologic relevance of this observation is essential before widespread phylloquinone supplementation is recommended.

## REFERENCES

- Sokoll LJ, Sadowski JA. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. *Am J Clin Nutr* 1996;63:566–73.
- Sokoll LJ, Booth SL, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA. Changes in serum osteocalcin, plasma phylloquinone, and urinary  $\gamma$ -carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. *Am J Clin Nutr* 1997; 65:779–84.
- Jie KS, Hamulyak K, Gijsbers BL, Roumen FJ, Vermeer C. Serum osteocalcin as a marker for vitamin K-status in pregnant women and their newborn babies. *Thromb Haemost* 1992;68:388–91.
- Knapen MHJ, Hamulyak K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. *Ann Intern Med* 1989;111:1001–5.

- Plantalech L, Chapuy MC, Guillaumont M, Chapuy P, Leclercq M, Delmas PD. Impaired carboxylation of serum osteocalcin in elderly women: effect of vitamin K1 treatment. In: Christiansen C, Overgaard K, eds. Abstracts: Third International Symposium on Osteoporosis, Copenhagen, Denmark. Copenhagen: Handelstrykkeriet Aalborg, Aps, 1990:345–7.
- Knapen MH, Jie KS, Hamulyak K, Vermeer C. Vitamin K-induced changes in markers for osteoblast activity and urinary calcium loss. *Calcif Tissue Int* 1993;53:81–5.
- Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. *J Bone Miner Res* 1994;9:1591–5.
- Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. *J Clin Invest* 1993;91:1769–74.
- Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. *Bone* 1996;18:487–8.
- Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. *J Clin Endocrinol Metab* 1997;82:719–24.
- Fiore CE, Tamburino C, Foti R, Grimaldi D. Reduced bone mineral content in patients taking an oral anticoagulant. *South Med J* 1990; 83:538–42.
- Philip WJU, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS. Decreased axial and peripheral bone density in patients taking long-term warfarin. *Q J Med* 1995;88:635–40.
- Resch H, Pietschmann P, Krexner E, Willvonseder R. Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon. *Eur Heart J* 1991;12:439–41.
- Sato Y, Honda Y, Kunoh H, Oizumi K. Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. *Stroke* 1997;28:2390–4.
- Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton LJ. Changes in bone density after exposure to oral anticoagulants: a meta-analysis. *Osteoporos Int* 1999;9:441–8.
- Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. *Arch Intern Med* 1999;159:1750–6.
- Rosen HN, Maitland LA, Suttie JW, Manning WJ, Glynn RJ, Greenspan SL. Vitamin K and maintenance of skeletal integrity in adults. *Am J Med* 1993;94:62–8.
- Piro LD, Whyte MP, Murphy WA, Birge SJ. Normal cortical bone mass in patients after long term coumadin therapy. *J Clin Endocrinol Metab* 1982;54:470–3.
- Lafforgue P, Daver L, Monties JR, Chagnaud C, de Boissezon MC, Acquaviva PC. Bone mineral density in patients given oral vitamin K antagonists. *Rev Rhum Engl Ed* 1997;64:249–54.
- Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. *Ann Intern Med* 1998; 128:829–32.
- Haroon Y, Bacon DS, Sadowski JA. Liquid chromatographic determination of vitamin K1 in plasma with fluorometric detection. *Clin Chem* 1986;32:1925–9.
- Price PA, Epstein DJ, Lothringer JW, Nishimoto SK, Poser JW, Williamson MK. Structure and function of the vitamin K-dependent protein of bone. In: Suttie JW, ed. *Vitamin K metabolism and vitamin K-dependent proteins*. Baltimore: University Park Press, 1980: 219–26.
- Booth SL, Sokoll LJ, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA. Assessment of dietary phylloquinone intake and vitamin K status in postmenopausal women. *Eur J Clin Nutr* 1995; 49:832–41.
- Jie KS, Gijsbers BL, Knapen MH, Hamulyak K, Frank HL, Vermeer C. Effects of vitamin K and oral anticoagulants on urinary calcium excretion. *Br J Haematol* 1993;83:100–4.

25. Bach AU, Anderson SA, Foley AL, Williams EC, Suttie JW. Assessment of vitamin K status in human subjects administered "minidose" warfarin. *Am J Clin Nutr* 1996;64:894-902.
26. Kindberg CG, Suttie JW. Effect of various intakes of phylloquinone on signs of vitamin K deficiency and serum and liver phylloquinone concentrations in the rat. *J Nutr* 1989;119:175-80.
27. Weber P. The role of vitamins in the prevention of osteoporosis—a brief status report. *Int J Vitam Nutr Res* 1999;69:194-9.
28. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. *Am J Clin Nutr* 1999;69:74-9.
29. Binkley NC, Suttie JW. Vitamin K nutrition and osteoporosis. *J Nutr* 1995;125:1812-21.
30. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Edouard C, Meunier PJ. Serum bone gamma-carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. *J Clin Invest* 1986;77:985-91.
31. Booth SL, Gundberg CM, McKeown NM, Morse MO, Wood RJ. Vitamin K depletion increases bone turnover. *J Bone Miner Res* 1999;14(suppl):S393 (abstr).
32. Binkley N, Engelke J, Krueger D. Osteocalcin may participate in calcium homeostasis. *J Bone Miner Res* 1999;14(suppl):S317 (abstr).
33. Parfitt AM. Plasma calcium control at quiescent bone surfaces: a new approach to the homeostatic function of bone lining cells. *Bone* 1989;10:87-8.
34. Parfitt AM. Bone and plasma calcium homeostasis. *Bone* 1987;8(suppl):S1-8.
35. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. *J Bone Miner Res* 1998;13:297-302.
36. Douglas AS, Robins SP, Hutchison JD, Poter RW, Stewart A, Reid DM. Carboxylation of osteocalcin in postmenopausal osteoporotic women following vitamin K and D supplementation. *Bone* 1995;17:15-20.
37. Pietschmann P, Woloszczuk W, Panzer S, Kyrle P, Smolen J. Decreased serum osteocalcin levels in phenprocoumon-treated patients. *J Clin Endocrinol Metab* 1988;66:1071-4.
38. Garber AK, Binkley NC, Krueger DC, Suttie JW. Comparison of phylloquinone bioavailability from food sources or a supplement in human subjects. *J Nutr* 1999;129:1201-3.
39. National Research Council. Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press, 1989.
40. Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ. Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. *Am J Clin Nutr* 1998;67:1226-31.
41. Sadowski JA, Hood SJ, Dallal GE, Garry PJ. Phylloquinone in plasma from elderly and young adults: factors influencing its concentration. *Am J Clin Nutr* 1989;50:100-8.
42. Kasim S. Cholesterol changes with aging: their nature and significance. *Geriatrics* 1987;42:73-82.
43. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. *Atherosclerosis* 1993;98:83-90.

